Newer anti-resorptive therapy using monoclonal antibodies targeting RANKL (Denosumab), has been shown to improve bone outcomes better than classic bisphosphonate therapy [159], is approved for use in glucocorticoid-induced osteoporosis, and is not associated with first dose reactions. Here, TNFSF11 is linked to osteoporosis.